文献速递乳腺癌

优替德隆联合卡培他滨对比卡培他滨治疗重度经治、蒽环和紫杉类耐药转移性乳腺癌的III期随机对照试验总生存最终分析

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
PubMed 文献 · Ann Oncol · 2020-11-11

BG01-1323L III期试验最终总生存分析纳入405例重度经治、蒽环和紫杉类耐药转移性乳腺癌患者,按2:1随机接受优替德隆联合卡培他滨或卡培他滨单药。联合组中位OS为19.8个月,单药组为16.0个月(HR=0.75,95%CI 0.59-0.94,P=0.0142),联合治疗显著改善OS,PFS和ORR更新分析仍支持联合组更优,安全性与此前报道相似。

要点

  • 优替德隆联合卡培他滨较卡培他滨单药显著延长OS(19.8 vs 16.0个月,HR=0.75)。
  • 联合组PFS和ORR更新分析仍优于单药组。
  • 安全性与此前报道相似,未出现迟发毒性或新安全信号。

核心结论

  • 对于重度经治、蒽环和紫杉类耐药的转移性乳腺癌患者,优替德隆联合卡培他滨较卡培他滨单药显著改善总生存。

研究设计与样本

  • III期随机对照试验BG01-1323L,共405例患者按2:1随机接受优替德隆联合卡培他滨或卡培他滨单药。
  • 优替德隆30 mg/m2静脉滴注每日1次,第1-5天,输注90分钟;卡培他滨1000 mg/m2口服每日两次,第1-14天;每21天为一周期。
  • 卡培他滨单药组剂量为1250 mg/m2口服每日两次,第1-14天,每21天为一周期。
  • 预设310例死亡事件后,以双侧α=0.05采用Kaplan-Meier法估计OS。

主要发现

  • 联合组中位随访19.6个月,单药组15.4个月。
  • 意向治疗人群中,数据截止时共发生313例死亡,联合组270例中203例,单药组135例中110例。
  • 联合组中位OS为19.8个月,单药组为16.0个月(HR=0.75,95%CI 0.59-0.94,P=0.0142)。
  • PFS和ORR更新分析显示联合治疗仍优于单药治疗。
  • 安全性在发生率、严重程度和特异性方面与此前报道相似,未出现迟发毒性或新安全关注。

关键数值与推荐

  • 联合组中位OS 19.8个月,单药组16.0个月,HR=0.75(95%CI 0.59-0.94),P=0.0142。

临床怎么用

  • 对于重度经治、蒽环和紫杉类耐药的转移性乳腺癌患者,可考虑优替德隆联合卡培他滨作为新的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary analysis of the phase III trial BG01-1323L demonstrated that utidelone plus capecitabine significantly improved progression-free survival (PFS) and overall response rate (ORR) versus capecitabine alone in heavily-pretreated patients with metastatic breast cancer (MBC). Here, we report the final overall survival (OS) analysis and updates of other endpoints. PATIENTS AND METHODS: In total, 405 patients were randomised 2:1 to receive utidelone (30 mg/m2 IV daily, days 1-5, over 90 min) plus capecitabine (1000 mg/m2 orally b.i.d., days 1-14) or capecitabine alone (1250 mg/m2 orally b.i.d., days 1-14) every 21 days. The secondary endpoint, OS, was estimated using the Kaplan-Meier product-limit approach at a two-sided alpha level of 0.05 after the prespecified 310 death events had been reached. Exploratory analyses of the primary endpoint, PFS, and the secondary endpoint, ORR, were also done. Safety was analysed in patients who had at least one dose of study drug. RESULTS: At the final OS analysis, the median duration of follow-up was 19.6 months in the utidelone plus capecitabine group and 15.4 months in the capecitabine alone group. In the intention-to-treat population, 313 deaths had occurred at data cut-off, 203 of 270 patients in the combination group and 110 of 135 in the monotherapy group. Median OS in the combination group was 19.8 months compared with 16.0 months in the monotherapy group [hazard ratio (HR) = 0.75, 95% confidence intervals (CI) 0.59-0.94, P = 0.0142]. The updated analysis of PFS and ORR showed that the combination therapy remained superior to monotherapy. Safety results were similar to those previously reported with respect to incidence, severity and specificity. No late-emerging toxicities or new safety concerns occurred. CONCLUSIONS: For heavily-pretreated, anthracycline- and taxane-resistant MBC patients, utidelone plus capecitabine significantly improved OS versus capecitabine alone. These results support the use of utidelone plus capecitabine as a novel therapeutic regimen for patients with MBC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Xu B, Sun T, Zhang Q, et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Ann Oncol. 2020. PMID: 33188874. doi:10.1016/j.annonc.2020.10.600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。